Author of

• 14451

  +

  P2.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 213)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Locoregional Disease – NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14484

    +

    P2.03-033 - ¹⁸FDG-PET/CT Improves Lung Cancer Staging and Treatment Selection Accuracy (ID 279)

    09:30 - 09:30  |  Author(s): V. Camacho
    • Abstract

    Background:
    Integrated [18]F-fluorodeoxyglucose Positron-Emission Tomography - Computed tomography ([18]FDG-PET/CT) has emerged as the new standard in staging and treatment planning for patients with lung cancer, not only improving the diagnostic accuracy of mediastinal nodal involvement but also the detection of metastases. The aim of this study is to analyse this data in our centre and to evaluate the treatment variations derived from the results of this technique.
    
    Methods:
    We included patients with proven or suspected lung cancer diagnosed between September 2010 and February 2014. A computed tomography (CT) and [18]FDG-PET/CT were performed in all patients, both explorations were evaluated separately, and a tumour-node-metastasis (TNM) stage and a specific treatment based on its results was established for each technique. We used the 7[th] TNM edition, and nodal stations were identified according to mapping system of the American Thoracic Society.
    
    Results:
    We included 249 patients, the median age was 65 years (23-88), the 78.7% were males and the 21.2% were females. Non-small cell lung cancer (NSCLC) represented an 86.3% and small-cell-lung cancer (SCLC) a 8%. In 14 patients (5.6%) no pathologic diagnosis was established. In 137 of 249 (55%) patients no change in staging between CT and [18]FDG-PET/CT was observed: 65 (47.4%) were stage I, 10 (7.2%) stage II, 22 (16%) stage IIIA, 22 (16%) stage IIIB and 18 (7.2%) stage IV. Compared with CT,[ 18]FDG-PET/CT provided additional information in 112 of 249 patients (45 %): 36 patients (14,4%) had downstaging, and a curative treatment was feasible in 13 patients (5.2%) (1 SCLC, 12 NSCLC). Seventy six patients (30.5%) had upstaging, and a palliative treatment was proposed to 49 of them (19.67%) (10 SCLC, 37 NSCLC, 2 without histology). **Of-line: occult metastases were detected in 49 of 249 patients, which represent a 19.67%.
    
    Conclusion:
    The study confirms that in our institution, integrated [18]FDG-PET/CT improves both lung cancer staging in all histologies and the treatment selection accuracy.